Don’t miss the latest developments in business and finance.

USFDA completes inspection of Nagpur facility, no observation issued: Lupin

Image
Press Trust of India New Delhi
Last Updated : Sep 14 2018 | 12:00 PM IST

Drug firm Lupin Friday said the US health regulator has completed inspection of its Nagpur facility in Maharashtra without any observation.

The product specific pre-approval inspection by USFDA concluded without any observation, Lupin said in a BSE filing.

Shares of Lupin were trading at Rs 972.80 apiece, up 1.72 per cent, from the previous close on BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Sep 14 2018 | 12:00 PM IST

Next Story